GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (WBO:EWLS) » Definitions » 3-Year FCF Growth Rate

Edwards Lifesciences (WBO:EWLS) 3-Year FCF Growth Rate : 0.30% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Edwards Lifesciences 3-Year FCF Growth Rate?

Edwards Lifesciences's Free Cash Flow per Share for the three months ended in Sep. 2024 was €0.44.

During the past 12 months, Edwards Lifesciences's average Free Cash Flow per Share Growth Rate was -35.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 0.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 2.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Edwards Lifesciences was 65.80% per year. The lowest was -17.20% per year. And the median was 11.10% per year.


Competitive Comparison of Edwards Lifesciences's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Edwards Lifesciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's 3-Year FCF Growth Rate falls into.



Edwards Lifesciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Edwards Lifesciences  (WBO:EWLS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Edwards Lifesciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.

Edwards Lifesciences Headlines

No Headlines